Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 22484116)

1.

Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.

Udoetuk JD, Dai Y, Ying GS, Daniel E, Gangaputra S, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group.

Ophthalmology. 2012 Aug;119(8):1569-74. doi: 10.1016/j.ophtha.2012.01.043. Epub 2012 Apr 6.

2.

Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy.

Rowbottom L, Stinson J, McDonald R, Emmenegger U, Cheng S, Lowe J, Giotis A, Cheon P, Chow R, Pasetka M, Thavarajah N, Pulenzas N, Chow E, DeAngelis C.

Ann Palliat Med. 2015 Apr;4(2):70-7. doi: 10.3978/j.issn.2224-5820.2015.04.07.

3.

High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review.

Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC.

J Arthroplasty. 2015 Apr 8. pii: S0883-5403(15)00234-X. doi: 10.1016/j.arth.2015.03.036. [Epub ahead of print] Review.

PMID:
25900167
4.

Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500 000 Person-year Study.

Shalom G, Zisman D, Bitterman H, Harman-Boehm I, Greenberg-Dotan S, Dreiher J, Feldhamer I, Moser H, Hammerman A, Cohen Y, Cohen AD.

JAMA Dermatol. 2015 May 1;151(5):533-8. doi: 10.1001/jamadermatol.2014.4956.

PMID:
25797026
5.

Immunosuppressive therapy and cancer risk in ocular inflammation patients: fresh evidence and more questions.

Khachatryan N, Kempen JH.

Ophthalmology. 2015 Feb;122(2):219-21. doi: 10.1016/j.ophtha.2014.11.023. No abstract available.

PMID:
25618424
6.

Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.

Yates WB, Vajdic CM, Na R, McCluskey PJ, Wakefield D.

Ophthalmology. 2015 Feb;122(2):265-73. doi: 10.1016/j.ophtha.2014.08.024. Epub 2014 Oct 11.

PMID:
25312044
7.

Inpatient glucocorticoid use: beneficence vs non-maleficence.

Dhatariya K.

Br J Hosp Med (Lond). 2014 May;75(5):252-6. doi: 10.12968/hmed.2014.75.5.252. No abstract available.

PMID:
25040268
8.

Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients.

Dilisio MF.

Orthopedics. 2014 Jul;37(7):e631-6. doi: 10.3928/01477447-20140626-54.

PMID:
24992058
9.

Glucocorticoid-induced hyperglycemia.

Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R.

J Diabetes. 2014 Jan;6(1):9-20. doi: 10.1111/1753-0407.12090. Epub 2013 Oct 29. Review.

PMID:
24103089
10.

Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?

Yates WB, McCluskey PJ, Wakefield D.

J Ophthalmic Inflamm Infect. 2013 May 31;3(1):48. doi: 10.1186/1869-5760-3-48.

11.

Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease.

Suelves AM, Arcinue CA, González-Martín JM, Kruh JN, Foster CS.

Ophthalmology. 2013 Jun;120(6):1201-9. doi: 10.1016/j.ophtha.2013.01.031. Epub 2013 Apr 16.

PMID:
23601800
12.

Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients.

Gonzalez-Gonzalez JG, Mireles-Zavala LG, Rodriguez-Gutierrez R, Gomez-Almaguer D, Lavalle-Gonzalez FJ, Tamez-Perez HE, Gonzalez-Saldivar G, Villarreal-Perez JZ.

Diabetol Metab Syndr. 2013 Apr 4;5:18. doi: 10.1186/1758-5996-5-18. eCollection 2013.

13.

Glucocorticoid-induced hyperglycemia.

Kwon S, Hermayer KL.

Am J Med Sci. 2013 Apr;345(4):274-7. doi: 10.1097/MAJ.0b013e31828a6a01. Review.

PMID:
23531958
14.

The high incidence of steroid-induced hyperglycaemia in hospital.

Fong AC, Cheung NW.

Diabetes Res Clin Pract. 2013 Mar;99(3):277-80. doi: 10.1016/j.diabres.2012.12.023. Epub 2013 Jan 5.

PMID:
23298665
15.

Corticosteroid-associated osteonecrosis: a rare, but serious, complication in uveitis.

Smith WM, Larson TA, Meleth AD, Krishnadev N, Nussenblatt RB, Sen HN.

Ocul Immunol Inflamm. 2013 Apr;21(2):102-7. doi: 10.3109/09273948.2012.740129. Epub 2012 Dec 19.

PMID:
23252656
16.

Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD004118. doi: 10.1002/14651858.CD004118.pub2. Review.

PMID:
23152224
17.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3. Review.

PMID:
23076890
18.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3. Review.

PMID:
23076889
19.

Corticosteroid-induced hyperglycemia is increased 10-fold in patients with pemphigus.

Alavi A, Lowe J, Walsh S, Juurlink D, Mortaz-Hedjri S, Shear NH.

Int J Dermatol. 2012 Oct;51(10):1248-52. doi: 10.1111/j.1365-4632.2012.05470.x.

PMID:
22994671
20.

Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.

Etminan M, Forooghian F, Maberley D.

CMAJ. 2012 May 15;184(8):E431-4. doi: 10.1503/cmaj.111752. Epub 2012 Apr 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk